BRCA2 mutations have been found to be associated with an increased mutational load [6–8], neoepitope formation [10], increased tumor-infiltrating lymphocytes [10], and a favorable response to immune checkpoint blockade [7, 25, 26]. Here, BRCA2 is linked to neoplasm.